Background

Clear cell ovarian carcinomas (CCOCs) are a distinct histopathological subtype and account for 5-10% of epithelial ovarian cancers (EOCs). They have a poor prognosis in advanced stages and at recurrence. They are commonly resistant to platinum-based chemotherapy and treatment options are limited in patients with progressive disease. Molecular profiling may identify patient subsets who could benefit from targeted therapies when standard treatment has failed and also provide an insight into the genomic heterogeneity of CCOC’s that share a similar phenotype.